


Cite this: *RSC Adv.*, 2024, 14, 23559

DOI: 10.1039/d4ra90079k


rsc.li/rsc-advances

## Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors

Yue Dong,<sup>a</sup> Min Liu,<sup>a</sup> Jian Wang,<sup>b</sup> Zhuang Ding<sup>a</sup> and Bin Sun<sup>\*a</sup>

Correction for 'Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors' by Yue Dong *et al.*, *RSC Adv.*, 2019, 9, 26302–26314, <https://doi.org/10.1039/c9ra03713f>.

The authors regret that an incorrect version of Fig. 8 was included in the original article. The correct version of Fig. 8 is presented here.



**Fig. 8** (A<sub>1</sub>–A<sub>6</sub>) Polarizing microscopy results of *Candida albicans* treated with the positive control drugs (fluconazole and terbinafine) and the target compounds (5, 6 and 8) at the specific concentration of 8 mg mL<sup>-1</sup>. (B<sub>1</sub>–B<sub>4</sub>) TEM results for *Candida albicans* treated with the target compound (8) at the specific concentration of 8 mg mL<sup>-1</sup>.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Institute of BioPharmaceutical Research, Liaocheng University, 1 Hunan Road, Liaocheng 252000, PR China

<sup>b</sup>Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China
